Back to Search
Start Over
Roche & Alnylam's phase II KARDIA-2 study of zilebesiran in people with hypertension meets primary endpoint
- Source :
- PharmaBiz. March 7, 2024
- Publication Year :
- 2024
-
Abstract
- Roche and Alnylam announced that the phase II KARDIA-2 study [NCT05103332] of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension (high blood pressure) - the leading [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.785577145